davemcconkey-tokms

Pharma and Life Sciences in Windsor: A Perspective from Executive David McConkey

Before my work became closely associated with Oxford, my career was shaped by time spent in and around Windsor. For many in UK and European pharma, Windsor is synonymous with commercial headquarters, regional coordination, and proximity to customers. As David McConkey Windsor, those years taught me lessons that continue to guide my work as Europe Region VP of Commercialisation in oncology.

Windsor as a commercial crucible

In Windsor, the focus was intensely commercial:

• Brand planning cycles.
• Sales and marketing alignment.
• Close monitoring of market uptake, competitive dynamics, and local payer responses.

The proximity to field teams and local affiliates meant we heard about payer objections, tender losses, or formulary delays in real time. It was here that I first saw how decisions about pricing and contracting could make or break access, long before JCA or MFN were part of the everyday vocabulary.

Understanding local payer issues from the ground up

The Windsor environment gave me early exposure to:

• Hospital pharmacy constraints and their negotiating power.
• Regional funding differences within countries.
• The growing influence of health technology assessment even at local levels.

We were already grappling with parallel trade as a reality, not a theoretical concern:

• Stockouts in one market linked to arbitrage from another.
• Confusion about list prices versus net prices and who saw which number.
• Frustration from clinicians when availability and affordability did not align.

These experiences created a deep respect for the operational complexity behind every neat strategy slide.

Complementing Windsor with Oxford

Later, as my role evolved and I became connected with the oncology and policy ecosystem around Oxford, I realised how complementary the two experiences were:

• Windsor taught me the day‑to‑day reality of commercial execution: brand teams, sales, local payers, and tendering.
• Oxford opened up the world of evidence generation, HTA design, and system‑level policy debates around JCA, MFN, and price management.

Together, they provided a 360‑degree view of European oncology commercialisation: from the meeting rooms where strategy is agreed to the hospitals where it is tested.

The enduring value of regional hubs

As more work becomes virtual and cross‑border, some question the future of regional hubs like Windsor. My view is that they remain critical because:

• They anchor global ambitions in real‑world market feedback.
• They facilitate cross‑functional collaboration that cannot be fully replicated on screens.
• They keep leaders close to the practical realities of payer interactions and local politics.

For me, the identity of David McConkey Windsor will always represent a formative period when I learned that success in European oncology is measured not just in trial results, but in the messy, human, and political work of getting therapies to patients.